Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using budding yeast to screen for anti-prion drugs.

Déborah Tribouillard1, Stéphane Bach, Fabienne Gug

  • 1CNRS UMR7150, Amyloids and Cell Division Cycle Laboratory, Station Biologique, Roscoff, Bretagne, France.

Biotechnology Journal
|August 8, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging role of G-quadruplexes in alternative splicing regulation.

Trends in genetics : TIG·2026
Same author

Identification of novel CLK1 inhibitors by computational fragment-based ligand design, co-crystallization, chemical synthesis and structure activity relationships.

European journal of medicinal chemistry·2026
Same author

Self-assembled PEGylated nanoparticles based on Elafibranor derivative 3d for the treatment of metabolic dysfunction-associated steatohepatitis.

Journal of biological engineering·2026
Same author

Sibiriline, a novel dual inhibitor of necroptosis and ferroptosis, prevents RIPK1 kinase activity and (phospho)lipid peroxidation as a potential therapeutic strategy.

Cell death discovery·2025
Same author

Research towards selective inhibition of the CLK3 kinase.

Beilstein journal of organic chemistry·2025
Same author

The codon context provides <i>cis</i>-acting immune evasion for the human papilloma virus (HPV) E6.

RNA (New York, N.Y.)·2025

Researchers developed a rapid yeast assay to find drugs for neurodegenerative prion diseases. This screening method identified compounds effective against yeast and mammalian prions, offering hope for new treatments.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Prions are misfolded proteins causing fatal neurodegenerative diseases like transmissible spongiform encephalopathies.
  • No effective treatments currently exist for prion-based diseases.
  • Prion propagation mechanisms are not fully understood but are critical for disease development.

Purpose of the Study:

  • To develop and validate a rapid, cost-effective, high-throughput screening method for identifying anti-prion compounds.
  • To identify novel drug candidates for treating prion diseases.
  • To explore conserved pathways in prion formation and maintenance.

Main Methods:

  • A two-step, yeast-based assay was developed for screening potential anti-prion drugs.
  • Compounds were tested in vivo against budding yeast prions ([PSI+] and [URE3]).

Related Experiment Videos

  • Efficacy was further assessed by evaluating mammalian prion clearance in three cell culture models.

    • Main Results:

    • The yeast-based assay successfully identified compounds effective against yeast prions.
    • Several identified compounds also promoted mammalian prion clearance in cell culture.
    • The results validate the assay as an efficient tool for drug discovery and structure-activity relationship studies.

    Conclusions:

    • The developed yeast assay is a validated, economic, and efficient high-throughput screening method for prion inhibitors.
    • Conserved biochemical pathways suggest potential for pharmacological intervention across species.
    • Identified compounds warrant further investigation in models of other amyloid-related diseases, including Alzheimer's and Parkinson's.